title: Predicting Vitality Change in Older Breast Cancer Survivors after Primary Treatment--an Approach Based on Using Time-related Difference of Pro-inflammatory Marker C-reactive Protein.
abstract: BACKGROUND
  We aimed to determine prognosis of vitality change and functional status of breast cancer survivors after primary oncological treatment using time-related differences of elevated levels of highly sensitive proinflammatory C-reactive protein (CRP).
  
  
  METHODS
  The test group consisted of 46 elderly breast cancer survivors (median age was 65 years) who completed Vitality Scale of Short Form 36 (SF-36) after completing treatment and another retrospectively at diagnosis. Data on tumor-related factors, treatment, and outcomes were obtained retrospectively from medical records, and linear regression analysis was performed. CRP was followed at diagnosis and one year after primary treatment. Within the scope of this study, clinically important difference in the Vitality Scale was set at five points of change.
  
  
  RESULTS
  Results showed a statistically significant relationship between CRP change and vitality component of SF-36 change (rs = - 0.350, p = 0.023) in which a decrease in CRP inversely correlated with the quality of life component. The overall change was 1.078 of the vitality scale score (approximately 1 point) for each 1 unit decrease of CRP (1 mg/ L). Association of CRP levels (before and after treatment, its difference between these time points) with age, number of comorbidities and stage of the disease was analyzed and no statistically significant relationship was found in our study.
  
  
  CONCLUSIONS
  Preliminary results suggested time-related differences in elevated CRP levels as a potentially suitable predictor for change in vitality status for long term, chronic condition for older breast cancer survivors. We suggest the interpretation schema including an understanding that CRP change of 5 mg/ L and more should be considered a potential risk factor for subsequent negative clinical outcomes.
authors.forename: K
authors.initials: K
authors.lastname: Skrivanova
authors.forename: L
authors.initials: L
authors.lastname: Anderkova
authors.forename: D
authors.initials: D
authors.lastname: Brancikova
authors.forename: J
authors.initials: J
authors.lastname: Jarkovský
authors.forename: K
authors.initials: K
authors.lastname: Benesova
authors.forename: N
authors.initials: N
authors.lastname: Elfmarková
authors.forename: T
authors.initials: T
authors.lastname: Svěrák
authors.forename: M
authors.initials: M
authors.lastname: Bendová
authors.forename: H
authors.initials: H
authors.lastname: Peterkova
authors.forename: J
authors.initials: J
authors.lastname: Nedvěd
authors.forename: M
authors.initials: M
authors.lastname: Protivánková
authors.forename: L
authors.initials: L
authors.lastname: Minar
authors.forename: E
authors.initials: E
authors.lastname: Holoubková
authors.forename: L
authors.initials: L
authors.lastname: Dusek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000097:blood / Q000401:mortality* / Q000523:psychology; D002097:C-Reactive Protein / Q000032:analysis*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011788:Quality of Life; D017741:Survivors
chemical_list: D002097:C-Reactive Protein